目的： 探讨lncRNAANRIL在胶质瘤患者组织标本中的表达及其临床意义。 方法： 收集2012年1月1日至2016年12 月30日于四川省人民医院就诊的临床资料完整的129例胶质瘤患者肿瘤组织及25例对照正常脑组织标本，应用Real-time PCR 检测lncRNAANRIL的表达水平，分析其表达与患者对替莫唑胺的敏感性及临床预后的关系。 结果： 与对照组脑组织标本比较， lncRNAANRIL在129例胶质瘤组织中的表达明显升高[ （8.730±0.336）vs（1.090 ± 0.137），t=9.957、P<0.01]，在WHO分级Ⅰ~Ⅱ级患 者中的表达明显低于Ⅲ~Ⅳ级[ （4.198±0.260）vs（10.550±0.291），t=13.03、P<0.01]，lncRNAANRIL的表达与患者的年龄、性别、术 前 KPS 评分、肿瘤直径无关（均P>0.05），与肿瘤WHO 分级、对替莫唑胺的敏感性及生存状态明显相关（均P<0.05）。低表达 lncRNAANRIL患者的总生存时间较高表达者明显延长[ （29.17±0.64）vs（13.54±0.74）个月，P<0.01]，低表达lncRNAANRIL患者 的无复发生存时间较高表达者明显延长[ （15.88±0.83）vs（9.08±0.56）个月，P<0.01]。单因素及Cox多因素回归模型分析提示, ln- cRNAANRIL的表达、WHO分级及对替莫唑胺的敏感性是胶质瘤独立的预后因素（P<0.05）。 结论： 胶质瘤患者的肿瘤病理级别 越高，lncRNAANRIL的表达越高，患者生存时间越短。lncRNAANRIL参与调节胶质瘤的发生发展，可作为胶质瘤诊断和预后 评估潜在的分子标志物。

Objective: To investigate the expression and clinical significance of lncRNAANRIL in glioma tissues. Methods: 129 cas- es of glioma tissues and 25 cases of normal brain tissues as control were collected from patients treated in Sichuan Provincial People’s Hospital from January 01, 2012 to December 30, 2016. Real-time quantitative PCR was used to detect the mRNA expression of ln- cRNAANRIL; and the relationship between lncRNAANRIL expression and sensitivity of patients to temozolomide as well as the clini- cal prognosis of glioma patients were analyzed. Results: Compared with control group, the expression of lncRNAANRIL in 129 cases of glioma tissues was significantly increased ([8.730±0.336] vs [1.090±0.137], t=9.957, P<0.01). The expression of lncRNAANRIL in WHO Ⅰ-Ⅱ grade patients was significantly lower than that of patients at grade Ⅲ-Ⅳ ([4.198±0.260] vs [10.550±0.291], t=13.03, P< 0.01). lncRNA ANRIL expression was significantly correlated with WHO stage，the sensitivity to temozolomide（TMZ）and survival status（all P<0.05）, but not associated with gender, age, KPS score and tumor size (all P>0.05). Moreover, Kaplan-Meier analysis dem- onstrated that decreased lncRNA ANRIL expression contributed to significantly longer overall survival ([29.17±0.64] vs [13.54±0.74] months, P<0.01) and recurrence-free survival time ([9.08±0.56] vs [15.88±0.83] months, P<0.01). Univariate and multivariate analysis also indicated that lncRNA ANRIL expression, WHO stage and chemosensitivity could be independent prognostic markers for glioma (P<0.05). Conclusion: Higher pathological grade of glioma patients indicates higher lncRNA ANRIL expression and shorter survival time. lncRNAANRIL is involved in the occurrence and development of glioma, and can be used as a molecular marker for the diagno- sis and prognosis of glioma.